Evidence map›Paper›PMID 39692912›Full record

SynthesisImmunologic research2024

SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review.

Vanshika Rustagi, Shradheya R R Gupta, Chandni Talwar, Archana Singh, Zhen-Zhu Xiao, Rahul Jamwal, Kiran Bala, Akash Kumar Bhaskar, Shekhar Nagar, Indrakant K Singh

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. WSMicromachines · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vanshika Rustagi *Department of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India.
Shradheya R R Gupta *Department of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India.
Chandni TalwarDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
Archana SinghDepartment of Plant Molecular Biology, University of Delhi (South Campus), New Delhi, 110021, India.
Zhen-Zhu XiaoDepartment of Biological Sciences, The George Washington University, Washington, D.C, 20052, USA.
Rahul JamwalDepartment of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India.
Kiran BalaDepartment of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India.
Akash Kumar BhaskarCSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, 110025, India.
Shekhar NagarDepartment of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India. snagar@db.du.ac.in.
Indrakant K SinghDepartment of Zoology, Deshbandhu College, University of Delhi, New Delhi, 110019, India. iksingh@db.du.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, COVID-19 is still striking after 4 years of prevalence, with millions of cases and thousands of fatalities being recorded every month. The virus can impact other major organ systems, including the gastrointestinal tract (GIT), cardiovascular, central nervous system, renal, and hepatobiliary systems. The resulting organ dysfunction from SARS-CoV-2 may be attributed to one or a combination of mechanisms, such as direct viral toxicity, disruptions in the renin-angiotensin-aldosterone system (RAAS), thrombosis, immune dysregulation, and ischemic injury due to vasculitis. SARS-CoV-2 vaccines effectively reduce the severity of the disease, hospitalizations, and mortality. As of October 2024, 13.58 billion vaccine doses have been administered, with an average of 6959 daily doses. Also, the boosters are given after the primary immunization in a homologous and heterologous manner. The vaccines imposed severe potential health side effects such as clotting or obstruction of blood vessels termed arterial or venous thrombosis, autoimmune damage of nerve cells (Guillain-Barré syndrome; GBS), intense activation of coagulation system (vaccine-induced thrombotic thrombocytopenia), acute ischemic stroke (AIS) and cerebral venous sinus thrombosis (CVST), myocarditis, pericarditis, and glomerular disease. Overall, it is essential to highlight that the significant benefits of COVID-19 vaccination far outweigh the low risk of conditions. mRNA-based vaccine technology has emerged as a rapidly deployable vaccine candidate and a viable alternative to existing vaccines. It has a very low probability of adverse health effects, confirmed by data represented by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Vaccine Adverse Event Reporting System (VAERS), Yellow card approved under CDC, WHO.

Indexed as

COVID-19COVID-19 VaccinesVaccinationGuillain-Barre SyndromeHumansCOVID-19 VaccinesPathophysiologyPost-vaccinationSARS-CoV-2VaccinationWHO

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.